NCT04938219

Brief Summary

Shivering is known to occur in around 40% of women as a side effect of neuraxial anaesthesia during caesarean section.Women undergoing caesarean section under neuraxial anaesthesia are randomised into either the treatment group or control group. Women in both groups are observed during caesarean section. This study is to test a non-pharmacological and non-invasive treatment with two groups, an intervention and a control group. In the intervention group, intraoperative shivering during caesarean section is treated by placing two surgical gloves filled with warm water into the women's hands. In the control group, women will be treated with the current standard of care, which does not include specific treatment of shivering.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 16, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 24, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

June 24, 2021

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

April 22, 2024

Status Verified

April 1, 2024

Enrollment Period

4.4 years

First QC Date

June 16, 2021

Last Update Submit

April 19, 2024

Conditions

Keywords

intraoperative shiveringcaesarean sectionneuraxial anaesthesia

Outcome Measures

Primary Outcomes (1)

  • Change in intensity of shivering measured on a 5-point scale

    Shivering is evaluated during caesarean section 5 minutes after intervention. Shivering is graded on a scale from 0 (No shivering) to 4 (Violent muscular activity that involves the entire upper body) .The score will be recorded before the intervention and at 2 and 5 minutes after initiation of the intervention, as well as after arrival at the recovery area. Score: 0 - No shivering. 1. \- No visible muscle activity, but one or more of piloerection, peripheral vasoconstriction or peripheral cyanosis (other causes excluded). 2. \- Muscular activity in only one muscle group. 3. \- Moderate muscular activity in more than one muscle group, but not generalized shaking. 4. \- Violent muscular activity that involves the entire upper body.

    at baseline, at 2 and 5 minutes after the first assessment, and in the post-anaesthesia recovery room (approx.1 hour)ent.

Secondary Outcomes (1)

  • Change in subjective comfort levels of the patients before and after the intervention on a 11-point scale

    at baseline, at 2 and 5 minutes after the first assessment, and in the post-anaesthesia recovery room (approx.1 hour)

Study Arms (2)

Shivering Treatment Group

EXPERIMENTAL

Participants will be observed, and intervention will begin when a shivering score of 2 or higher is reached. The participants in the treatment group will receive one glove filled with warm water into each hand.

Other: Gloves filled with warm tap water

Control Group

NO INTERVENTION

Participants in the control group will only be observed, and not given additional treatment for the shivering.

Interventions

The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands

Shivering Treatment Group

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Ability to give informed consent
  • Age older than 18 years and younger than 40 years.
  • Gestational age \>36 weeks
  • Shivering during regional anaesthesia for caesarean section

You may not qualify if:

  • Inability to give informed consent
  • Latex allergy
  • Receiving combined spinal epidural anaesthesia (CSEA)
  • Secondary spinal anaesthesia for caesarean section in patients with unsatisfactory epidural labour analgesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Kantonsspital Baden AG, Department of Anaesthesiology

Baden, Canton of Aargau, 5404, Switzerland

RECRUITING

University Hospital Basel; Department of Anaesthesiology

Basel, 4031, Switzerland

RECRUITING

Related Links

Study Officials

  • Bigna Buddeberg, MD

    University Hospital, Basel, Switzerland

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bigna Buddeberg, MD

CONTACT

Melanie Dussy +41 76 422 6774

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Women undergoing caesarean section under neuraxial anaesthesia will be randomised into either the treatment group or control group (2 arms).
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 16, 2021

First Posted

June 24, 2021

Study Start

June 24, 2021

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

April 22, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Trial and participant data will be handled with uttermost discretion and is only accessible to authorised personnel who require the data to fulfil their duties within the scope of the study. On the eCRFs and other study specific documents, participants are only identified by a unique participant number. Trial and participant data will be handled with uttermost discretion and is only accessible to authorised personnel who require the data to fulfil their duties within the scope of the study. On the eCRFs and other study specific documents, participants are only identified by a unique participant number. The participant identification list will be stored in a locked place by the sponsor-investigator. Password access to the eCRFs will only be given to the investigators directly enrolled in recruitment of participants and capturing of data.

Locations